---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002863"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:35:16.240490+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Novavax reaffirms full year 2024 guidance; presents at J.P. Morgan conference

## Summary
- Reaffirmed full year 2024 financial guidance, no specific figures provided.
- Preliminary expectations for combined R&D and SG&A expenses for 2025 and 2026 mentioned without numbers.
- Presenting strategic updates at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.

## SEC filing metadata
- accession: 0001104659-25-002863
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925002863/0001104659-25-002863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925002863/tm253091d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002863
- JSON: https://secwatch.observer/filing/0001104659-25-002863.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.